Genetic Technologies Limited's Comment on Sales, Marketing and Customers
The company operates primarily in the Asia-Pacific region and the U.S. market, marketing and distributing breast cancer risk assessment tests, including BREVAGen™, BREVAGen plus, and GeneType for Breast Cancer. These tests are intended for women at risk of developing sporadic, or non-hereditary, breast cancer, including Caucasian, African American, and Hispanic populations. The company targets large comprehensive breast treatment and imaging centers in the U.S., where its products are utilized in medical clinics and breast health centers. Its U.S. subsidiary, Phenogen Sciences Inc., now renamed geneType Inc., is incorporated in Delaware and responsible for marketing and distributing these tests across the United States. Other entities mentioned in filings include geneType Inc. and Perlegen Sciences, Inc.
In a significant move that underscores its commitment to advancing genomics in healthcare, Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has announced its partnership with CancerIQ, an online platform that boasts access to 45 healthcare systems and 250 clinics across the United States. This collaboration, unveiled on September 11, 2024, positions Genetic Technologies to leverage CancerIQ’s expansive network and enhance its offerings in cancer risk assessment and management.Genetic Technologies has established itself as a global leader in genomics-based tests, particularly in health and serious diseases, making the partnership with CancerIQ a potentially transformative step. The partnership is expec...
GTG Unveils Ambitious Digital Media Sales Campaign to Tap into Growing U.S. Wellness Testing MarketGenetic Technologies Limited (GTG), a leading provider of genetic risk assessment tests, has recently announced its plans to launch an extensive targeted digital advertising campaign in the United States. The main of this campaign is to drive widespread consumer interest and participation in GTG s geneType Risk Assessment Tests, also known as Consumer Initiated Testing (CIT). Set to commence at the end of March 2024, this campaign will gradually scale up throughout the year and position GTG to access a significant portion of the projected $4.9 billion U.S. wellness testing market by 2032.According to recent ma...
Genetic Technologies Limited’s Comment on Sales, Marketing and Customers
The company operates primarily in the Asia-Pacific region and the U.S. market, marketing and distributing breast cancer risk assessment tests, including BREVAGen™, BREVAGen plus, and GeneType for Breast Cancer. These tests are intended for women at risk of developing sporadic, or non-hereditary, breast cancer, including Caucasian, African American, and Hispanic populations. The company targets large comprehensive breast treatment and imaging centers in the U.S., where its products are utilized in medical clinics and breast health centers. Its U.S. subsidiary, Phenogen Sciences Inc., now renamed geneType Inc., is incorporated in Delaware and responsible for marketing and distributing these tests across the United States. Other entities mentioned in filings include geneType Inc. and Perlegen Sciences, Inc.
Sources:
Genetic Technologies Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Genetic Technologies Limited’s corporate clients.
For your research, we’ve provided 9 tables on Genetic Technologies Limited corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
80.4 %